Summary
- Dompé U.S., Inc. has agreed to pay $32 million to settle allegations of kickbacks involving patient assistance foundations.
- The allegations claim that from 2018 to 2021, Dompé paid Medicare beneficiary co-payments to encourage the purchase of its drug, Oxervate.
- This settlement addresses serious violations related to healthcare fraud and patient assistance programs.
- The resolution underscores the ongoing scrutiny of pharmaceutical companies' practices in patient support initiatives.
Join the discussion — sign up to comment, upvote, and save articles.